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Abstract:Seventypercent of ovarian cancer patientsdiedue toconsecutive episodesof recurrences resulting from the re-growth
of ovarian tumor cells resistant to conventional chemotherapies. In an effort to identify chemoresistance mechanisms, we
compared the expression of genes in tumor cells isolated from the ascites of advanced-stage serous ovarian cancer patients prior
to (chemonaive,CN) andafter chemotherapy treatments (chemoresistant/recurrent, CR). A novel, recently publishedmethodwas
used for the isolation of tumor cells from the ascites of CN and CR patients. Illumina HT-12 platform was used to assess the
differential expressionof genes (DEGs) between the isolated tumor cells from the ascites ofCNandCRpatients. The identiﬁcation
of DEGswas achieved by comparing the genetic signatures of CN versusCR samples by amean expression ratio (fold change) of
2 and P < 0.05. Validation of selected genes was performed by quantitative Real Time Polymerase Chain Reaction (qRT-PCR).
The dominant canonical pathways in the CR versus CN tumor cells were determined by Ingenuity Pathway Analysis. Gene
expression analysis revealed differential expression of 414 genes, with 179 genes up regulated and 235 down regulated in theCR
group. There were signiﬁcant differences in gene expressions encoding for proteins involved with cancer stem cells, cell-cell
adhesion, embryonic development, tumor suppression, immune surveillance, retinoic acid and energymetabolism in tumor cells
isolated from CR compared to CN patients. Pathway analysis revealed that changes in cell cycle pathways, prominently those
involved with mitosis and polo-like kinase (PLK1), G2/M DNA damage and proteins linked with cell cycle checkpoint regulation
associated with chemoresistance. This preliminary molecular proﬁling, on a small number of patient samples, suggests an
important discrimination of genes in the isolated tumor cells derived from the ascites of CN andCRpatients. This type of study on
a larger cohort of samples may have important clinical implications for the development of therapeutic strategies to overcome
chemoresistance and associated recurrences in ovarian cancer patients.
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INTRODUCTION
Ovarian cancer represents 3% of all the new cancer cases
inAmericanwomen, but accounts for 5% of all the cancer-
related deaths [1]. This discrepancy occurs due to the
resistance of ovarian cancer patients to current chemo-
therapy regimens resulting in the deaths of 70% of the
patients within the first five years of diagnosis [2]. The vast
majority of ovarian cancer patients diagnosed with an
advanced-stage disease undergo debulking surgery fol-
lowed by adjuvant chemotherapy consisting of a platinum
agent (typically carboplatin) alone or in combination with
a taxane (paclitaxel) [2]. Initially, seventy percent of the
women respond to this therapy, but unfortunately the
majority of these patients eventually relapse due to
drug-resistant recurrent disease and die due to peritoneal
metastasis [3]. Disappointingly, the five year survival
period of these patients has remained unchanged and as
low as 30% for the last thirty years [4].
Metastasis in ovarian cancer is unique as it is usually
localized within the peritoneal cavity and derives directly
from the ovaries and/or the fallopian tubes to the adjacent
organs (extraovarian pelvic organs, colon, bladder and
liver) and/or by the attachment of exfoliated cancer cells
which survive as cellular aggregates and are carried by the
peritoneal tumor fluid (ascites) to surrounding organs in
the peritoneal cavity [5–8]. The presence of ascites is
associated with a poor prognosis [4, 9]. Microscopic
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inspection of ascites display a complex heterogeneous
picture of cellular environment constituting single cells,
floating multicellular aggregates of non-adherent cells,
cancer-associated fibroblasts, myeloid cells, activated
mesothelial cells and cancer stem cells (CSCs) [10–12].
Extensive seeding of these floating cells on the uterus,
sigmoid colon and omentum is frequently encountered
in advanced-stage and recurrent patients and ultimately
leads to disruption of major organs and eventually death
[7]. During the course of recurrence, cells within the
small microscopic residual cellular aggregates release
soluble pro-angiogenic mediators, which diffuse out
from the tumor population and bind to endothelial cells
of mature blood vessels leading to angiogenesis, which
sets the tumor expansion and recurrence in motion [13].
Hence, the presence of floating cellular aggregates,
commonly known as spheroids, in the ascites of ovarian
cancer patients is strongly associated with recurrence,
and there is an urgent need to study these spheroids in
the ascites in order to establish the mechanisms of
recurrence.
Mechanisms underlying the development of resistance
to platinum-based agents have been well characterized in
other cancers and include DNA repair mechanisms,
altered cellular transport of the drugs, increased antioxi-
dant production, and reduction of apoptosis [14–16].
Elevated gene expression affecting cellular transport,
DNA repair, apoptosis, cell-extracellular matrix and
cell-cell adhesion has been observed in ovarian cancer
patient’s samples resistant to platinum-based therapy
[17–19]. Taxanes were originally used as an alternative
to platinum based agents in order to overcome platinum
resistance in patients [20]. The development of taxane
resistance has also been well studied and characterized
[21, 22]. Typical mechanisms of paclitaxel resistance
involve alteration in drug transport, altered expression of
microtubule proteins, expression of taxane metabolizing
proteins and altered cell signaling resulting in reduced
apoptosis [22–25]. The roles of some of these factors in
cancer patients in response to taxane treatment (e.g.
altered expression of class IIIb-tubulin, reduced apoptosis
conferred by survivin expression and metabolism of tax-
anes by cytochrome P450 reductase) have also been
implicated in clinical samples [23–25].
It is still not known if the mechanisms of resistance to
‘combination chemotherapy’ are a combined response
of tumor cells to single agents or if a novel mechanism
of resistance exists that is different from the resistance
mechanisms observed with single agents. In recent
studies, we have demonstrated ovarian CSCs to be
involved with resistance to both platinum and taxane-
based chemotherapies [26, 27]. We and others have also
shown recurrent ovarian tumors to be enriched with
CSCs and mediators of pathways that regulate CSCs,
suggesting that CSCs may contribute to the development
of recurrence [10, 11, 28, 29].
To date most of the research conducted to understand
the chemoresistance mechanisms have used cancer cell
lines and few data are available on the relevance of these
studies on the potentialmechanisms of chemoresistance in
clinical samples [30, 31]. In recent studies, gene expres-
sion profiles of chemonaive (primary tumors obtained
during debulking surgery) and post chemotherapy tumors
have been analyzed to determine themolecular signature/s
associated with chemoresistance [17, 32]. These studies,
although important, used tumor sections, which are likely
to present a complex molecular profile of not only che-
moresistant tumor cells but also associated stroma and
infiltrated cells. As a consequence, these mixed genetic
profiles may not truly represent the associated pathways
regulating chemoresistance in tumor cells; hence, such
results may misrepresent the targets proposed for future
therapeutic interventions. Isolated tumor cells that survive
chemotherapy treatments in patients are likely to experi-
ence changes in gene expression allowing them to with-
stand the selective pressure of the drugs. These
phenotypically changed tumor cells are likely to exhibit
a molecular signature associated with chemoresistance
when compared to the gene expression profile of isolated
tumor cells before chemotherapy treatment.
In the present study, we have used our recently
described novel separation technique to isolate tumor cells
from the ascites of advanced-stage CN and CR serous
ovarian cancer patients [10]. Ascites samples were col-
lected from patients (not matched) at the time of surgery
prior to chemotherapy treatment (CN) and at different time
points during recurrence (CR). In this preliminary study,
changes in gene expression associated with chemoresis-
tance and recurrence were analyzed on a small set of
unmatched CN (n ¼ 4) and CR (n ¼ 4) samples by a
microarray gene expression profiling method. This study
aimed to (i) identify the molecular signature associated
with the isolated ascites-derived tumor cells of CR
patients; (ii) provide novel information about specific
genes that regulate the chemoresistant/recurrent pheno-
type of ascites-derived CR tumor cells, and (iii) provide an
insight into cellular pathways that regulate chemoresis-
tance in ascites-derived CR ovarian tumor cells. Our data
identified novel genes and associated pathwayswhichmay
have clinical relevance in designing therapeutic interven-
tions for ovarian cancer patients. To our knowledge this is
the first study, which has demonstrated a distinct molec-
ular profile of isolated tumor cells from the ascites of CR
patients.
MATERIALS AND METHODS
Patient Recruitment
Ascites were collected from patients diagnosed with
advanced-stage serous ovarian adenocarcinoma after
obtaining written informed consent under protocols
approved by the Research and Human Ethics Committee
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(HEC # 09/09) of The Royal Women’s Hospital,
Melbourne, Australia. The histopathological diagnosis,
tumor grades and stages were determined by independent
staff pathologists as part of the clinical diagnosis. Ascites
(As) samples (500 ml-2L) were obtained during surgery
from patients with primary carcinoma (n ¼ 7), and at the
time of recurrence (n ¼ 6) (Table 1). Apart from As22
which was collected twice from the same patient (As22C
and D) during sequential ascites removal within a month,
other samples were from individual cases. CN patients
(n¼ 7) did not receive any chemotherapy. All CR patients
(n¼ 6)were diagnosedwith a recurrent diseasewithin 1–8
months after completion of their first line of chemotherapy
treatment (Table 1). These patients had partial response to
the first and subsequent lines of chemotherapy. The che-
motherapy agents administered to patients, and the num-
ber of chemotherapy cycles varied from patient to patient
and are indicated in Table 1. In CR group, ascites was
collected frompatients at recurrence after the patients have
received the cycles of chemotherapy described in Table 1.
Isolation of tumor cells from the ascites of ovarian
cancer patients
Tumor cells from ascites were separated using the method
described previously [10]. Briefly, cells were collected
from ascites by centrifugation and cleared of red blood
cells by hypotonic shock. The remaining cells were then
cultured on 6-well low attachment plates for 3–4 days and
both adherent (non-tumorigenic, stromal cells) and non-
adherent (tumorigenic) cells were screened for fibroblast
Table 1. Description of serous ovarian cancer patients recruited for this study
Samples Stage Grade Age
Time of first
recurrence (after
completion of first
line of chemotherapy)
Time of sample
collection
(after diagnosis)
Patient
status
Treatment received before
the collection of ascites
Study technique
used
As31 IIIc G3 54 NA AD CN None Microarray
As36 IIIc G3 59 NA AD CN None Microarray and
validation
As37 IIIc G3 48 NA AD CN None Microarray and
validation
As35 IIIc G3 90 NA AD CN None Microarray and
validation
As59 IIc G3 64 NA AD CN None Validation
As82 IIIc G3 48 NA AD CN None Validation
As86 IIIa Unknown 51 NA CN none Validation
As22C IIIc Unknown 54 1 month 10 months #CR Carboplatin and Paclitaxel (3 cycles),
Doxorubicin (4 cycles), AMG386
Topotecan (2 cycles),
Cyclophosphamide (2 cycles)
Microarray and
validation
As22D IIIc Unknown 54 1 month 11 months #CR Carboplatin and Paclitaxel (3 cycles),
Doxorubicin (4 cycles), AMG386
Topotecan (2 cycles),
Cyclophosphamide (3 cycles)
Microarray
As34 Unknown G3 65 4 months 1 year #CR Carboplatin and Paclitaxel (6 cycles) Microarray and
validation
As39 Unknown 80 7 months 1 year 5 months #CR Carboplatin and Paclitaxel (6 cycles),
Liposomal Doxorubicin (6 cycles)
Microarray and
validation
As60 IIIc G3 52 4 months 2 years #CR Cisplatin and Paclitaxel (6 cycles),
AMG-386 182 (Clinical Trial,
8 cycles)), Paclitaxel (3 cycles),
Paragon Trial (Anastrozole,
2 Cycles), Cisplatin (3 cycles)
Validation
As72 IIIc G3 62 8 months 2 years 9 months #CR Carboplatin and Paclitaxel (6 cycles),
Gemcitabine and Carboplatin
(6 cycles)
Validation
As73 IIIc G3 56 6 months 2 years 9 months #CR Carboplatin and Paclitaxel (6 cycles),
AMG-386 182 Trial (9 cycles),
Paclitaxel (6 cycles),
Cyclophosphamide (2 cycles),
Topotecan (2 cycles), Liposomal
Doxorubicin (2 cycles)
Validation
G3-Poorly differentiated; NA-Not applicable; #CR - ascites was collected after the patients had undergone the above described cycles of chemotherapy; AD-
After diagnosis, before treatment.
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surface protein (FSP), cancer antigen 125 (CA125) and
cytokeratin 7 (CK7) by flow cytometry to assess the purity
of each fraction [10]. The non-adherent epithelial tumor-
igenic population rich in CK7 andCA125 and lacking FSP
and vimentin was processed further for microarray
analysis.
Flow cytometry analysis
The flow cytometrymethod has been described previously
[33]. All data were analysed using Cell Quest software
(Becton-Dickinson, Bedford, MA, USA). Results are
expressed as mean intensity of fluorescence (MIF).
Immunofluorescence analysis
Immunofluorescence analysis was performed as described
previously [33]. Images were captured using the Leica
TCS SP2 laser, and viewed on a HP workstation using the
Leica microsystems TCS SP2 software.
RNA extraction and microarray analysis
Isolated tumor cells were homogenised in TRIzol. RNA
extracts >3 mg from clinical samples (Table 1) were
outsourced to Australian Genome Research Facility
(AGRF) Melbourne, Australia for microarray processing.
The Illumina (Sentrix Human HT12v4) platform with
47,232 probes was used as described before [34, 35].
Briefly, the Agilent BioAnalyser 2100 was used to deter-
mine the quality and integrity of the RNA using the
NanoChip method (Agilent Technologies, USA). A total
of 500 ng of RNA was labeled using the Total Prep RNA
amplification kit (Ambion, USA). 1.5 ug of labeled cRNA
was prepared for hybridisation to the Sentrix Human-
HT12 Beadchip by preparing a probe cocktail that includ-
ed GEX-HYB Hybridisation Buffer (Illumina).
A total hybridisation volume of 30 ml was loaded into a
single array on the Sentrix Human-HT12 Beadchip. The
chip was hybridised at 58C for 16 h in an oven with a
rocking platform and washed using the appropriate pro-
tocols as outlined in the Illumina manual (http://support.
illumina.com/documents/MyIllumina/3466bf71-78bd-4842-
8bfc-393a45d11874/WGGEX_Direct_Hybridization_Assay_
Guide_11322355_A.pdf), and then coupledwithCy3 and
scanned in the Illumina iScan scanner. The scanner
operating software, GenomeStudio was used to process
measured signal intensities into a text file for analysis.
Analysis of the microarray data
This was performed by AGRF. Raw signal intensity data
from Illumina HT-12 slides (www.illumina.com) were
background corrected within GenomeStudio. Mean
signal intensities were calculated per sample. Individual
signal intensities were floored to a value 10% of the mean
signal intensity of the array, i.e. to a value of 40. This step
was performed to eliminate negative expression values
whereoriginal, non-backgroundsubtracted intensitieswere
within the background range. Data were log2 transformed,
and quantile normalized in Partek Genomics Suite 6.5
(www.Partek.com). Only probes with a coefficient of
variation of more than 5% were further considered
(n ¼ 17,163). A t-test assuming unequal variance was
performed, with a bootstrap multiple testing correction
(200 randomizations). Gene ontology enrichment
analysis was performed in Partek (Genomics Suite
6.5), using either the default gene ontology categories
or the KEGG GO database (www.genome.jp/kegg/).
Enrichment Fisher exact p-value was calculated based
on the number of genes in the provided gene list in
relation to the number of genes in gene groups in the
genome annotation file. The enrichment score was
calculated as negative antilog of that p-value. The
larger the enrichment score, the higher the enrichment
of that functional group in the provided gene list.
The identification of DEGs was achieved by comparing
the genetic signatures of CN versus CR samples and was
defined by amean expression ratio (fold change or FC) of 2
and a P-value cut-off of 0.05. The gene expression data
was analyzed using the established two-dimensional hier-
archical clusters of genes in the form of a color-codedHeat
Map. A Principal Component Analysis (PCA) generated
byPartekGenomics Suite 6.6was used to translate the data
into a three-dimensional image whereby the dimension-
ality of the data set was reduced to a sphere-like repre-
sentation while maximizing the discrimination between
the groups [36].
Ingenuity pathway analysis
The molecular interactions of the canonical pathways
between the tumor cells of CN and CR ovarian cancer
patientswas established by correlating the results obtained
from the gene expression datawith geneswhose biological
functions are known in the literature using Ingenuity
Pathway Analysis (http://www.ingenuity.com). The CR-
associated DEGs list containing the 414 unique genes was
filtered using the criteria of FC > 2 and P < 0.05.
Ingenuity recognizes the Illumina identifiers and gene-
rated common pathways or molecular connections
between the CR and CN isolated ascites tumor cells.
Representations of the molecular relationship between
CN and CR ascites tumor cells were generated based on
FC> 2 and P< 0.05 using Benjamini-Hochbergmultiple
resting correction values.
Quantitative Real Time Polymerase Chain Reaction
(qRT-PCR) Analysis
Validation of selected genes identified by microarray
analysis was performed by qRT-PCR. RNAwas extracted
from ascites-derived tumor cells using TriZol from the six
different CN and CR patients described in Table 1.
Extracted RNA was quantified using the NanoDrop-
2000 Spectrophotometer (NanoDrop Technologies INC).
RNA quality and integrity were verified by agarose gel
electrophoresis. Complementary DNA (cDNA) was
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synthesized from 500 ng of RNA using the High Capacity
cDNA Transcription Kit (Applied Biosystmes, CA, USA)
as per manufacturer’s instructions. PCR reactions were
performed in triplicate with negative controls where water
was used in place of reverse-transcribed template included
for each primer pair to exclude PCR amplification of
contaminating DNA. The primers used for qRT-PCR are
summarized in Table 2. A PCR product was amplified for
each set of primers, purified using the QIAquick Gel
Extraction Kit (Qiagen), quantified using the NanoDrop-
2000 Spectrophometer and verified by size by agarose gel
electrophoresis. The PCR product was then diluted from
500 fg to 0.5 fg and was used as a standard for quantitative
analysis. Absolute quantification of PCR products was
performed as described previously [37].
RESULTS
Morphology of cells collected from the ascites of
ovarian cancer patients
Ascites cells derived frombothCN (n¼ 4) andCRpatients
(n ¼ 3) were assessed by phase contrast microscopy after
seeding on low attachment plates for 24 h. Two distinct
populations of cellswere observed: (i)multicellular aggre-
gates (spheroids) that floated as three-dimensional
structures in the growth medium without attachment
(Figure 1A), and (ii) spindle shaped fibroblast-like single
cells that adhered to the low attachment plates (Figure 1C).
Morphological assessment of the spheroids revealed a
three dimensional cluster of cells loosely compacted
together and surrounded by layers of cells (Figure 1A).
In general spheroids were in the form of loose aggregates
Table 2. Human oligonucleotide primer sequences for quantitative real-time PCR
Gene Symbol Accession no. Primer sequences from 50-30 Size (bp)
Data Capture
Temp (C)
ADAMTS9 NM_182920.1 Forward 191 78
CGAAAAACCTGCCGTAATGT
Reverse
TCAGAGTCTCCATGCACCAG
BCL11A NM_022893.3 Forward 206 80
NM_018014.3 CTCTCCTCCCCTCGTTCTG
NM_138559.1 Reverse
CTTCCGTGTTCGCTTTCTAAGTA
CLDN1 NM_021101.4 Forward 301 81
ACTCCTTGCTGAATCTGAGCAGC
Reverse
CCAGTGAAGAGAGCCTGACC
CLDN16 NM_006580 Forward 233 80
CTCCCTGATGAGCCGTACAT
Reverse
AGAACAGCTCCAGCCAAAAA
CRABP2 NM_001878.3 Forward 198 80
NM_001199723.1 CGGAAAACTTCGAGGAATTG
Reverse
CATCCACAGTCTGCTCCTCA
PAX8 NM_003466.3 Forward 387 82
AAGGTGGTGGAGAAGATTGG
Reverse
GCTGCTCTGTGAGTCAATGC
PROM1 NM_006017 Forward 167 78
ATTGGCATCTTCTATGGTTT
Reverse
GCCTTGTCCTTGGTAGTGT
Rn18S NR_003286.1 Forward 153 80
GTAACCCGTTGAACCCCATT
Reverse
CCATCCAATCGGTAGTAGCG
SerpinA3 NM_001085.4 Forward 190 78
GCTCATCAACGACTACGTGAA
Reverse
CACCATTACCCACTTTTTCTTGC
TGFBR3 NM_003243.2 Forward 331 80
ACATGGATAAGAAGCGATTCAGC
Reverse
AACGCAATGCCCATCACGGTTA
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of small clusters of cells with a defined outer rim
(Figure 1A). After 24 h on tissue culture plastic, most
spheroids attached to the plates and there was a transfor-
mation from a three dimensional structure to flattened
cellular clusters containing several layers of cells adherent
on top of each other (Figure 1B). The periphery of the
spheroids showed thin elongated cells moving out of the
spheroid whereas cells towards the centre were more
rounded in structure. As the cells moved away from the
centre, cell-cell contact was reduced resulting in the slow
disaggregation of the spheroid (Figure 1B). On the other
hand, single cells attached to the plastic as elongated
spindle-like cells having a fibroblast-like morphology
(Figure 1D).
Assessment of cell surface markers by flow
cytometry
Single cells and spheroids (dispersed by trypsinization)
were characterized by the cell surface expression of FSP,
CA125, and CK7 by flow cytometry. High expression of
CA125 and CK7 was observed in the cells dispersed from
spheroids, while no expression of FSP was evident
(Figure 1E). On the other hand, the single cells were
positive for FSP and no expression of CA125 and CK7
was evident (Figure 1F).
Analysis by immunofluorescence
We next analyzed the expression and localization of
vimentin in ascites samples by immunofluorescence. Con-
sistent with the flow cytometry results, no expression of
vimentin was observed in the cells within the spheroids
(Figures 2B-C). Vimentin expression was only evident in
cells protruding out of spheroids (Figures 2B-C). On the
other hand, single cells demonstrated strong expression of
vimentin (Figure 2E-F). Vimentin expression was evident
in both cytoplasm and membrane of single cells
(Figures 2E-F).
Heat Map and Principal Component analysis
Eight ascites-derived spheroid tumor samples were
used to determine the gene expression changes in CN
and CR tumor cells derived from the ascites of ovarian
cancer patients. A pool of 47,232 probes was used to
assess the expression of 18,009 genes. To analyse the
variation in gene expression between the CN and CR
groups, two dimensional colour-coded Heat Maps were
generated using the filtering criteria of FC > 2 and P <
0.05 (Figure 3). The genes represented in yellow are up
regulated, while those represented in red are down
regulated in the respective CN or CR groups. The Heat
Map demonstrated a distinct separation of genes in CN
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Figure 1. Morphological features and expression of surface markers of ascites-derived spheroids and single cells. (A) Spheroids and (C)
single cells were seeded on low attachment plates immediately after collection. Morphological features of (B) spheroids and (D) single cells on
tissue culture plastic after 24 h following seeding. Images were assessed by a phase contrast microscope. Magnification was 100x, scale bar ¼
50mm.The images are representative of n¼ 14 samples. (E-F) Flowcytometric assessment of purified cells from the ascites ofCN (n¼ 7) andCR
(n¼ 7) ovarian cancer patientswas performed by incubating the cellswith either control IgG or relevant primary antibodies against the respective
antigens followed by incubationwith secondary phycoerythrin conjugated antibody. Results are representative of (n¼ 14) independent samples.
The filled histogram in each figure represents control IgG, black lines indicate protein expression in respective cells.
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and CR tumor groups. Genes which were up regulated
in the CR group were down regulated in the CN group
and vice versa, suggesting that these two groups are
distinctly different from each other (Figure 3A). This
was supported by the PCA mapping of 83.4% obtained
between the CN and CR spheroid tumor samples
(Figure 3B). These observations were consistent with
PC1 values of 70.1% along the x-axis which indicates
significant genetic variation between the CN and CR
groups, while the small PC2 variation of 6.66% indi-
cates small variation of samples within the same
groups.
Figure 3. Differential expression of genes (DEGs) inCNandCRsamples. (A)TheHeatMap analysis of geneswas performed at P< 0.05 and
FoldChange>2. The gene expression analysis is based on 433 probes representing 414DEGs.DEGs in theCNandCR samples are displayed in a
color-coded matrix which is divided into four large rectangular boxes representing the up regulated (yellow) or down regulated (red) genes. The
columns along the x-axis (from right to left), are the clinical samples [CN n¼ 4, followed by CR (n¼ 4)]. The intensity of colors are indicative of
how positively (yellow) or negatively (red) these 414 genes are detected by 433 probes. (B): PCA analysis of genes at P< 0.05 and fold change
>2. The PCA which contributes to the overall differences in the CN and CR groups is noted at the top of the graph. Variation between the CN
(grey) and CR (red) groups are indicated by spheres.
FSP-
FSP+
Spheroids
A B C
D E F
Single cells
20X 20X 20X
20X20X 20X
FSP- FSP-
FSP+ FSP+
Figure 2. Expression of vimentin in spheroids and single cells. (A-F)Purified spheroids and single cells were evaluated for the expression and
localization of vimentin by immunofluorescence using mouse monoclonal antibody (green) as described in the Methods andMaterials. Cellular
stainingwas visualized using the secondaryAlexa 488 (green) fluorescent labeled antibody, and nuclear stainingwas detected byDAPI (blue).A
andD, cellswere only stainedwithDAPI (blue),B andE, cellswere stainedwith anti-vimentin followed byAlexa 488 (green),C andF overlay of
DAPI and vimentin staining. Magnification was 200x; scale bar ¼ 50 mm.
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Changes in gene expression associated with
chemoresistance and recurrence in isolated ascites
tumor cells
A total of 414 genes were identified to be differentially
expressed between the CN and CR groups. Of these 190
probes representing 179 genes were up regulated and 243
probes representing 235 genes were down regulated in the
CR spheroid tumor samples. The 20 most up regulated or
down regulated genes are presented in Tables 3 and 4,
respectively. Of the 20 up regulated genes, 4 genes were
unknown (Table 3). Three genes, LAMA3, CPN8 and
PAX8, were identified twice with different probes. Genes
involved with cell-cell adhesion such as CLDN16,
CLDN1, LAMA3 [38–40] and inhibition of metastasis and
angiogenesis, ADAMTS9 [41] topped the list (Table 3).
This was followed by genes involved in embryonic devel-
opment such asUCA1 [42], TGFbR3 [43] and PAX8 [44].
In addition, phospholipid binding protein CPNE8 [45],
calcium channel regulators AHNAK2 [46], proteins
involved with intravascular modelling of lipoproteins,
LIPG [47] and monocarboxylate transporter, SLC16A5
[48] were also included in the list (Table 3).
Of the twenty most down regulated proteins, Serpin A3
involved with inflammatory reactions topped the list [49]
(Table 4). The majority of the proteins in the twenty most
down regulated list were associated with tumor infiltration
and endothelial cells as well as host immunity. These
included HCLS1 [50], SOX 18 [51], HOXB5 [52], HLA-
DRB4 [53], LY9 [54], IF116 [55],CD99 [56], andBCL11A
[57]. Tumor suppressor genes such as FBP1 [58],RASSF2
[59] were also included in the top twenty list of down
regulated genes. In addition, the cell cycle regulator
CDKN3 [60], inhibitor of cellular migration FGD3 [61],
and regulator of cytokinesis KIF20A [62] were also in
the top 20 down regulated genes. However, HOXB2,
which has previously been shown as a regulator in breast
tumorigenesis was lost in CR ascites tumor cells [63]. In
addition GLIPR2, a regulator of fibrosis and EMT [64],
RGS2, a regulator of G protein signalling 2 involved
with cellular stress [65] PSRC1, proline/serine- rich
coiled-coil 1 which functions as a microtubule destabi-
lizing protein and controls mitotic progression [66] and
PMP22, peripheral myelin protein 22 shown to be
involved with modulation of alpha6 integrin in human
endometrium [67] was down regulated in CR tumors.
The differential distribution of genes in the isolated CR
compared to CN tumor cells obtained from the ascites of
ovarian cancer patients is demonstrated in Figure 4. The
microarray expression data has been uploaded as
Supplementary Table 1.
Table 3. 20 most up regulated genes in CR compared to CN ascites tumor cells (FC > 2, P < 0.05)
Gene Symbol Probe ID P-value FC Gene Name Gene Function
CLDN16 5960102 0.013 26.39 Claudin16 Cell-cell adhesion [38]
ADAMTS9 1570382 0.002 22.40 A disintegrin and
metalloproteinase with
thrombo-spondin type 1, motif 9
Involved in the cleavage of proteoglycans,
the control of organ shape during
development, and inhibition of angiogenesis [43, 79]
UCA1 4250367 0.015 18.88 A non-protein-coding RNA Embryonic development and cancer associated RNA [42]
CLDN1 5960296 0.030 16.49 Claudin1 Cell-cell adhesion [39]
LAMA3 6480592 0.026 16.00 Laminin,alpha3 Mediate attachment, migration, organization of
cells during embryonic development [40]
LAMA3 2650612 0.040 12.11 Laminin,alpha3 Same as above
LOC651957 5560707 0.008 11.70 Unknown Unknown
C140RF78 3390551 0.041 10.84 AHNAK nucleoprotein Calcium channel regulators [46]
CPNE8 1470386 0.042 10.34 Copine 8 Phospholipids binding protein [45]
AHNAK2 5260594 0.023 10.08 AHNAK nucleoprotein Calcium channel regulators [46]
KIF13B 5290209 0.008 9.78 Kinesin family member 13B Transport of phosphatidylinosito
(3,4,5)-triphosphate in neurons
PAX8 4850070 0.030 9.53 Paired box 8 Embryonic developmental gene frequently expressed
in cancer including ovarian cancer [44, 87]
PROM1 7400452 0.022 9.33 Prominin1, CD133 Transmembrane protein expressed on adult stem cells.
Suppresses differentiation [100, 101]
CPNE8 580592 0.045 9.13 Copine 8 Phospholipids binding protein [45]
TGFbR3 3190379 0.036 6.70 Type III transforming
growth factor-beta
receptor (betaglycan)
Embryonic development and loss of the
receptor in cancer [43, 92]
C200RF46 730491 0.016 5.32 Unknown Unknown
LIPG 7210681 0.046 5.94 Endothelial lipase Intravascular modelling of lipoproteins [47]
C1ORF116 730491 0.016 5.32 Unknown Unknown
LOC642299 6020561 0.024 5.15 Unknown Unknown
SLC16A5 6860082 0.0192 5.14 Solute carrier family 16
(monocarboxylate
transporter) member 5
Involved in the transport of monocarboxylate across
the plasma membrane. It is postulated that it has
function in the disposition of drugs [48]
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Gene ontology enrichment analysis identified three
major functional types of DEGs in the CR group. These
functions included cellular components (e.g. chromosom-
al regulation, mitosis, cytoskeletal organization, etc),
biological processes (e.g. regulation of nuclear division,
organelle localization, mitoses, cytokinesis, cell cycle,
cellular component assembly, etc) and molecular func-
tions (e.g.microtubulemotor activity, gene transcriptional
repressor activity, etc). This data has been provided in
Supplementary Table 1.
Validation of candidate genes by qRT-PCR
We next selected 6 genes from themost up regulated and 3
genes from the down regulated candidates to validate
using qRT-PCR.Most of the selected genes had previously
been associated with ovarian cancer progression, except
ADAMTS9 which had not been linked to ovarian cancer.
Twelve samples (CN¼ 6 andCR¼ 6) (Table 1) were used
to validate the microarray gene expression changes in CN
and CR tumor cells isolated from the ascites of ovarian
cancer patients (Figure 5).
There was a significant difference in 5 out of the 6
candidate up regulated genes selected from the microar-
ray. These genes were involved with cell-cell adhesion
such asCLDN16 (P< 0.05),CLDN1 (P< 0.01), the tumor
suppressor gene ADAMTS9 (P < 0.05) involved with
inhibition of metastasis and angiogenesis and genes
involved in embryonic development such as TGFbR3
Table 4. 20 most down regulated genes in CR compared to CN ascites tumor cells (FC > 2, P < 0.05)
Gene Symbol Probe ID P-value FC Gene Name Gene Function
SerpinA3 6280168 0.0056 26.39 Serine protease inhibitor3 Associated with the inflammatory reactions [49]
HOXB2 3460097 0.030 16.46 Homeobox transcription
factor 2
Involved in normal development and cancer [63]
HCLS1 1300408 0.018 9.00 Hematopoietic cell-specific
Lyn substrate 1
Highly expressed in human myeloid cells and
involved with the endocytic pathway required
for the Ag presentation of dendritic cells [50]
SOX18 6100433 0.010 8.35 Sex determining region
Y box 18
Involved with the development of
lymphangiogenesis and metastasis [51]
HOXB5 1470500 0.022 8.34 Homeobox transcription
factor B5
Involved in the differentiation of angioblasts
to mature endothelial cells [52]
CRABP2 3400296 0.024 7.34 Cellular Retinoic acid
binding protein 2
Involved in vitamin A homeostasis [109–110]
HLA-DRB4 7330398 0.0100 7.33 Major histocompatibility
complex, class II, DR beta 4
Involved with the presentation of class II
molecules by antigen presenting cells [53]
GLIPR2 830278 0.026 7.02 Glioma pathogenesis-related
protein 2
Mediator of fibrosis and EMT [64]
PMP22 7560138 0.035 6.60 Peripheral myelin protein 22 Expressed in myelinating neurons
and pancreatic cancer [67]
RGS2 3400019 0.043 6.50 Regulator of G protein
signalling 2
Component of cellular stress [65]
LY96 70167 0.022 6.32 Lymphocyte antigen 96 Associates with toll-like receptor 4 and
confers responsiveness to
lipopolysaccyaride (LPS) [54, 107]
CD99 4290097 0.011 6.01 Cell surface glycoprotein Involved in leukocyte migration and
T cell adhesion. Also act as an
oncosuppressor in osteosarcomas [56]
PSRC1 1070762 0.015 5.75 Proline/serine- rich coiled-coil 1 Functions as a microtubule destabilizing
protein that controls mitotic
progression also known as DDA3 [65]
CDKN3 5260014 0.10 5.62 Cyclin-dependent
kinase inhibitor 3
Dual specificity protein phosphatase
which inactivates CDK2 [60]
RASSF2 5390095 0.040 5.52 Ras association domain
family 2
Tumor suppressor gene frequently
silenced in cancer [59]
BCL11A 6580450 0.0256 5.42 B-cell CLL/lymphoma 11A
(zinc finger protein)
Involved in lymphoma pathogenesis [57]
FGD3 5270619 0.006 5.35 FYVE, RhoGEF and
PH domain containing 3
Inhibit cell migration [61]
FBP1 6020224 0.042 5.34 Fructose 1,6 phosphatase Key energy metabolism enzyme [58]
KIF20A 1050195 0.012 5.31 Kinesin family member 20A Required for the mitotic exit of cells
during cytokinesis [62]
IFI16 3870594 0.046 5.26 Interferon gamma inducible
protein 16
Mediates anti-inflammatory actions of type 1
interferon through suppression of activation
of caspases by inflammasomes [55]
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CR tumor
cells analyzed
at P<0.05, 
FC>2
Genes involved with
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Embryonic stem cells
Cancer stem cells
Genes up regulated    
(FC~ 2-26 fold)
Genes down regulated 
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energy metabolism 
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Figure 4. Differential distribution
of genes in the isolated CR com-
pared to CN tumor cells obtained
from the ascites of ovarian cancer
patients. Cellular functions are
assigned to genes which were evalu-
ated at P< 0.05 and Fold Change (FC)
>2.
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Figure 5. Validation of genes by q-PCR. (A) The absolute gene expression value of six genes up regulated and (B) three down regulated in CR
compared to CN samples. RNA from CN (n ¼ 6) and CR (n ¼ 6) was extracted, cDNA was prepared and q-PCR for CLDN-1, CLDN-16,
ADAMTS9, PROM1, PAX8, TGFBR3, Serpin A3, BCL11A andCRABP2was performed and the resultant mRNA levels were quantified from the
standards prepared as described in theMaterial andMethods section. The experimentswere performed on six independent CNandCR samples in
triplicate. Significant intergroup variations are indicated by  P < 0.05, P < 0.01.
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(P < 0.05) and PAX8 (P < 0.01) (Figure 5A). However,
PROM1, also known as the common ovarian cancer stem
cell marker CD133, was not significantly enhanced in the
CR group compared to the CN group in a set of 6 samples
analysed although the trend of enhanced expression was
evident. Although all three down regulated genes selected
for validation, SerpinA3, BCL11A and CRABP2, did not
show significant differences between the CN and CR
groups, the decreasing trend in CR compared to CN group
was evident (Figure 5B).
Changes in gene expression in As22D compared to
As22C
Ascites 22C was obtained from a chemoresistant and
recurring patient who had received sequential doses of
chemotherapy listed inTable1 (carboplatin andpaclitaxel)
(3 cycles), doxorubicin (4 cycles), AMG386 topotecan
(2 cycles), cyclophosphamide (2 cycles). Ascites 22Dwas
drained from the same patient within a month after the
patienthad receivedanadditional cycleof cyclophosamide
(number of chemotherapy cycles received ¼ carboplatin
and paclitaxel (3 cycles), doxorubicin (4 cycles), AMG386
topotecan (2 cycles), cyclophosphamide (3 cycles).
Even though both samples overlapped each other in PCA
plot (Figure 3B), some genetic differences was evident in
the Heat Map (Figure 3A). On further investigation, 16
differentially expressed genes (8 up and down regulated in
both cases) with a fold-change of>2-fold was observed in
As22DcomparedtoAs22C.Thegenesare listed inTables5
and 6.
Ingenuity pathway analysis
To elucidate the underlying biological significance of
DEGs identified by the microarray analysis between the
CN and CR groups, Ingenuity Pathway Analysis was
performed on the gene set identified using FC > 2 and
P < 0.05 criteria. This was performed to identify the
canonical pathways that uniquely regulate the chemore-
sistant phenotype of ascites tumor cells. With a data set
of 414 DEGs (179 up regulated and 235 down regulat-
ed), 172 canonical pathways were identified. The gene
content of the CR-associated 414 DEGs list correspond-
ing to 433 probes was used for the generation of the
biological networks using the Analyze Networks algo-
rithm. The genes listed within the 414 DEG list were
connected based upon their known relationship or
Table 5. 8 up regulated genes in Ass22C compared to AS22D tumor cells (FC > 2)
Gene Symbol Probe ID FC Gene Name Gene Function
APOF 130400 5.3 Apolipoprotein F Secreted sialoglycoprotein that resides on the HDL and LDL fractions
of human plasma. Human ApoF is also known as Lipid Transfer
Inhibitor protein (LTIP) based on its ability to inhibit cholesteryl
ester transfer protein (CETP)-mediated transfer events between
lipoproteins [111]
KCNH6 7000064 3.2 Potassium voltage-gated channel,
subfamily H, member 6
Voltage-gated potassium channels functions include regulating
neurotransmitter release, heart rate, insulin secretion, neuronal
excitability, epithelial electrolyte transport, smooth muscle
contraction, and cell volume [112].
KYNU 3460685 3.4 Kynureninase Is a pyridoxal-50-phosphate (pyridoxal-P) dependent enzyme that
catalyzes the cleavage of L-kynurenine and L-3-hydroxykynurenine
into anthranilic and 3-hydroxyanthranilic acids, respectively.
Kynureninase is involved in the biosynthesis of NAD cofactors
from tryptophan through the kynurenine pathway [113]
LRAP 1010296 3.5 ERAP2 endoplasmic
reticulum aminopeptidase 2
Aminopeptidases hydrolyze N-terminal amino acids of proteins or
peptide substrates. Major histocompatibility complex (MHC)
class I molecules rely on aminopeptidases such as LRAP to trim
precursors to antigenic peptides in the endoplasmic reticulum (ER)
following cleavage in the cytoplasm by tripeptidyl peptidase II [114]
MAGT1 3190625 3.7 Magnesium transporter 1 A critical regulator of basal intracellular free magnesium
(Mg(2C)) concentrations [115]
MAL 4040398 3.7 T-cell differentiation protein Highly hydrophobic integral membrane protein belonging to the MAL
family of proteolipids. The protein has been localized to the
endoplasmic reticulum of T-cells and is a candidate linker protein
in T-cell signal transduction. In addition, this proteolipid is localized
in compact myelin of cells in the nervous system and has been
implicated in myelin biogenesis and/or function. The protein plays
a role in the formation, stabilization and maintenance of
glycosphingolipid-enriched membrane microdomains.
Down-regulation of this gene has been associated with a variety
of human epithelial malignancies [116]
MGC26356 3930255 2.7 Zinc finger protein 876, pseudogene Not known
MRP63 750450 4 Mitochondrial ribosomal protein 63 Not known
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functions associated with CR-dependent genes in the
Ingenuity Pathways Knowledge Base. These networks
were unique for CR-associated DEGs and are described
in Supplementary Table 2. The majority of the pathways
identified by Ingenuity Pathway Analysis were implicated
in cancer, cellular growth and proliferation, cellular
development, mitosis/cell cycle regulation, cellular
assembly and organization. The top ten pathways are
described in Table 7. Of these, the pathway regulated
by the PLK1 associated with Cell Cycle and DNA damage
topped the list (Table 8). The principal genes involved in
these pathwaysCDC25c, CCNB1 andPLK1were all down
regulated in CR tumors compared to CN tumors (Table 8).
Potential involvement of PLK1, CDC25c and CCNB1 in
response to chemotherapy (DNA damage response)
leading to G2-M cell cycle arrest and initiation of
mitosis are depicted in Figures 6A and B.
DISCUSSION
To our knowledge, this is the first study which describes a
genomewidemicroarray transcriptional profiling analysis
on a small set of isolated tumor cells obtained from the
ascites of advanced-stage CN and CR serous ovarian
cancer patients. This was performed to specifically iden-
tify CR-associated genes and pathways that could be
involved in the recurrence and subsequent progression of
serous ovarian cancer. By combining our novel method of
isolating ovarian tumor cells from the ascites of ovarian
cancer patients with gene microarray analysis we were
able to compare the gene expression profiles between CN
and CR tumor cells without any back ground noise from
the associated stromal cellular component.
Using the criterion FC > 2 and P < 0.05, this study
demonstrated a unique gene expression profile of isolated
tumor cells prior to and after chemotherapy as evidenced
Table 6. 8 down regulated genes in As22C compared to As22D tumor cells (FC > 2)
Gene Symbol Probe ID FC Gene Name Gene Function
ADCY3 3800050 4.8 Adenylate cyclase 3 Membrane-associated protein which catalyzes the formation
of cyclic adenosine-30,50-monophosphate (cAMP) [117]
ASS1 110433 3 Arginosuccinate synthetase Rate limiting enzyme for arginine synthesis [118]
ASS1 2640544 3 Same as above Same as above
C11orf63 1740767 7.5 chromosome 11 open reading frame 63 Uncharacterised protein
C3ORF34 1850040 4 centrosomal protein 19, also
known as CEP19
This gene localizes to centrosomes and primary cilia and
co-localizes with a marker for the mother centriole.
This gene resides in a region of human chromosome
3 that is linked to morbid obesity [119]
IL-8 1570553 3.2 Interleukin-8 Pro-inflammatory tumor promoting cytokine [120]
IL-8 1980309 4.2 Same as above Same as above
LCN2 4390398 3.5 Lipocalin -2, also known as neutrophil
gelatinase-associated lipocalin (NGAL)
Adipokine/cytokine implicated in obesity and inflammation [121]
LRG1 6660162 2.3 Leucine-rich alpha-2-glycoprotein-1 Extracellular ligand for cytochrome C and acts as a survival factor [],
In the presence of transforming growth factor-b1 (TGF-b1),
is mitogenic to endothelial cells and promotes angiogenesis [122]
MT1A 6200402 2.8 Metallothionein 1A Small, cysteine-rich proteins which have been implicated in
various forms of stress providing cytoprotective action
against oxidative injury, DNA damage and apoptosis [123]
Table 7. Top ten Ingenuity Pathway analysis
Ingenuity Canonical Pathways P-value Molecules involved
Mitotic Roles of Polo-Like Kinase 3.24E-05 CDC25b, CDC25c, PLK-1, PPP2CB, CDC20, Cdk-1, CCNB1, ESPL1
Cell-Cycle:G2/M DNA Damage Checkpoint Regulation 1.32E-04 CDC25b, CDC25c, PLK-1, CDC20, CDK-1, CCNB1, CKS1B
Role of Checkpoint Proteins in Cell Cycle
Checkpoint Regulation
5.25E-04 CDC25c, PLK-1, Cdk-1, PPP2CB, ATMIN,SLC19A1
Lysine Degradation II 3.31E-03 AASDHPPT, ALDH7A1
Lysine Degradation V 3.31E-03 AASDHPPT, ALDH7A1
Herediatary Breast Cancer Signaling 5.89E-03 CDC25c, Cdk-1, RB1, POLR2C, POLR2J, CCNB1, SLC19A1
Acyl Carrier Protein Metabolism 1.86E-02 AASDHPPT
Asparagine Biosynthesis I 1.86E-02 ASNS
Protein Ubiquitination Pathway 2.09E-02 USP14, USP3, Cdc20, DNAJC4, DNAJB14, DNAJB5, UBE2C,
UBE2E3, UBE2L3
Cholesterol Biosynthesis I 2.34E-02 TM7SF2, SC5DL
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by the large number ofDEGs (n¼ 414), ofwhich 179were
up regulated and 235 were down regulated. The Heat Map
and PCA analyses suggested a distinct separation with
little overlap among the CR and CN associated genes.
Overall, CR tumors displayed a unique up regulation of
genes with functional relevance to cell-cell adhesion and
tight junctions, embryonic development, cancer stem
cells, tumor suppressor and genes involved in calcium
and phospholipid signaling.
Claudins 1 (CLDN1) and 16 (CLDN16), which topped
the up regulated list of genes, showed significant differ-
ences by validation at the mRNA level, are cell-cell
Table 8. Expression of common genes listed in the top three Ingenuity Pathway Analysis
Gene Symbol Probe ID P-value FC (CR/CN) Gene Name Gene Function
CDC25C 3460152 0.0066 4.71 cell division cycle 25C,
also known as PPP1R60
This gene is highly conserved during evolution and it plays a key
role in the regulation of cell division. It is a tyrosine phosphatase
and directly dephosphorylates cyclin B-bound CDC2 and triggers
entry into mitosis. It is also thought to suppress p53-induced
growth arrest [112].
CDC25C 4200451 0.00126 3.67 Same as above Same as above
CDC25C 6110706 0.0254 2.78 Same as above Same as above
CCNB1 6450397 0.0448 2.652 Cyclin B1 The gene product complexes with p34(cdc2) to form the
maturation-promoting factor (MPF) that is expressed
predominantly during G2/M phase [112]
CCNB1 4590040 0.0261 2.566 Same as above Same as above
PLK1 6130215 0.044 2.680 Serine/threonine-
Polo-like kinase 1
It is an early trigger for G2/M transition. It phosphorylates and
activates CDC25C, a phosphatase that dephosphorylates and
activates the cyclinB/CDC2 complex for entry of cells in
G2-M phase [111, 112]
Potential role of PLK-1 in CR tumors after chemotherapy treatment
(G2-M arrest) 
DNA damage or 
microtubule stabilization
ATM/ATR-P
‘on’
‘on’
Chk1-
P/Chk2-P
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Figure 6. Potential involvement of PLK1, CDC25c
and CCNB1 in response to chemotherapy treat-
ment in ascites-derived tumor cells. (A) In response
to chemotherapy treatment ATM, ATR, chk1 and
chk2 kinases are activated which causes nuclear
exclusion of CDC25c in residual ascites-derived
tumor cells. This results in mitotic arrest in prepara-
tion for DNA repair. PLK1 in that case is inactivated
by active ATM or ATR response. (B) After DNA
repair checkpoint kinases are silenced, phosphatases
can reverse the inhibition enforced by checkpoint
kinases so that PLK1 can be activated with concom-
itant activation of CCNB1-CDK1 complex. This
results in themitotic entry of cells with repairedDNA.
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adhesion proteins that form the backbone of the apico-
lateral tight junctions and are crucial for epidermal barrier
function [68]. These proteins are also essential for main-
taining epithelial cell polarity [69]. In ovarian cancer, high
expression ofCLDNS 3, 4, 5 and 7 have been reported to be
involved with tumorigenesis [70–72]. Over expression of
CLDN4 has also been shown to contribute to platinum
resistance in ovarian cancer [73]. Even though significant-
ly enhanced expression of CLDN1 has been demonstrated
in ovarian carcinoma effusions and is associated with poor
survival [74], enhanced expression of CLDN1 and
CLDN16 in CR compared to CN ascites-derived tumor
cells has not been reported before.
Changes in gene expression profiles and corresponding
epigenetic changes have been observed in cancer cells and
embryonic stem cells [75, 76]. Hence, it was not surprising
to note high expression of several embryonic stem cell
genes inCR tumor cells, suggesting that therapy resistance
programming of CR tumor cellsmay rely on the functional
attributes of genes required for embryogenesis. Of the
genes involved with embryogenesis, ADAMTS9was most
up regulated (FC > 22) [77]. ADAMTS9 has been
described as a tumor suppressor gene in a number of
cancers including oesophageal and nasopharyngeal car-
cinoma [78]. In addition, ADAMTS9 is also involved with
the cleavage of proteoglycans such as versican and aggre-
can [79]. Versican and aggrecan are important stromal
components of ovarian carcinomas and have been shown
to be involved with metastatic dissemination and angio-
genesis of ovarian cancer cells [80]. Enhanced ADAMTS9
expression in CR tumors may indicate low versican
expression, due to higher proteolytic cleavage, resulting
in the suppression of the stromal component and concom-
itant reduction in ovarian tumor cell dissemination outside
the peritoneal environment [81]. This is consistent with
our previous studies where we have demonstrated a rel-
atively low stromal component in CR compared to CN
ascites tumor cells [10]. Increased versican in the carci-
noma stroma associates with poorer outcomes, possibly
due to the facilitated migration of carcinoma cells away
from the tumor [80, 81], and versican has also been shown
to mediate mesenchymal epithelial transition to facilitate
metastasis of breast carcinoma cells in the lungs [82–84].
We also demonstrate significantly higher expression of
other embryonic and tumor suppressor genes such as
PAX8 [44], TGFbR3 [85], andUCA1 [42] in CR compared
to CN tumor cells. Of these three genes, significantly
enhanced expression of PAX8 and TGFbR3was validated
by qRT-PCR in CR ascites-derived tumor cells compared
to CN tumor cells. PAX8 is a lineage-restricted transcrip-
tion factor that plays an essential role in the organogenesis
of theMullerian duct [86]. In the reproductive tract, PAX8
expression is restricted to secretory cells of the fallopian
tube epithelium [87], which recent reports have suggested
as the cell of origin of serous ovarian cancer [88]. As such,
PAX8 has been shown to be overexpressed in ovarian
cancers [87] and amplified in 16% of primary ovarian
serous tumors [89]. Selective suppression ofPAX8 expres-
sion has been shown to induce apoptotic cell death in
ovarian cancer cell lines, suggesting that PAX8 is required
for the proliferation of ovarian cancer cells [89]. Contrary
to the expression ofPAX-8, the expression of TGFbR3 has
been shown to be down-regulated in the majority of
ovarian carcinomas and this was shown to be progressive
with increasing tumor grade [90]. TGFbR3 expression had
been shown to have a significant inhibitory effect in
ovarian cancer invasiveness, migration and the levels of
MMP-2 and MMP-9 by promoting tumor suppressor
effects of inhibin [90], as well as antagonizing the signals
received by TGFb [91, 92]. We have previously demon-
strated that tumor cells from the ascites of CN and CR
patients lack MMP-2 and MMP-9 expression [10]. This is
also consistent with the immotile and non-aggressive
nature of recurrent ovarian cancer where tumor growth is
localized within the peritoneum microenvironment and is
more dependent on dissemination by landing onto perito-
neal organs rather than aggressive invasion through the
vasculature [7]. As the expression of TGFRb3 is main-
tained by epigenetic transcriptional changes [90] it can be
contemplated that CR tumor cells may undergo genetic
reprogrammingevent under repetitiveDNAdamage repair
processes resulting in cells with relatively high expression
of TGFRb3 [93, 94]. However, the level of expression of
the soluble form of TGFbR3, generated by ectodomain
shedding of the cell surface receptor, yet remains to be
investigated in the context of CN and CR tumors.
Ovarian cancer has been classified as a stem cell disease
[95–97]. A recent study has presented a stem-like classi-
fication of high-grade serous tumors with poor patients’
survival [98]. PROM1 (CD133) a transmembrane glyco-
protein has been defined as a marker for ovarian cancer
stem cells [99], and the expression of PROM1 in ovarian
tumors has been associated with poor prognosis [100] and
is directly regulated by epigenetic modification [101]. In
our study, these observations were supported by the
significantly enhanced expression of PROM1 in CR
(FC> 9.30) compared to CN tumors by gene microarray.
However, validation of PROM1 in CR versus CN samples
did not gain significance even though an increasing trend
in CR samples was evident. This was probably due to the
small number of samples tested for this study. We have
also previously demonstrated enhanced expression of
PROM1 and other CSC markers in ovarian cancer cell
lines and tumor cells isolated from the ascites of ovarian
cancer patients in response to in vitro chemotherapy
treatment [26, 27]. In addition, we have also demonstrated
the emergence of CSC-like phenotype inmouse-xenograft
models on intraperitoneal administration of chemotherapy
after inoculation of ovarian cancer cells [27, 29, 97, 102].
These findings are consistent with the microarray data
provided in Supplementary Table 1 which shows
significant enhanced expression of PDGFRb and JAG1
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among the top 30 genes in CR (FC > 4.80 and 4.30)
compared to CN tumor cells. PDGFRb and JAG1 have
been associated with epithelial mesenchymal transition
and CSCs in pancreatic cancer [103]. Thus, further studies
on recurrent ovarian tumors in preclinical and clinical
settings are needed to understand how CSC markers such
as PROM1, PDGFRb and JAG1 signals to support stem
cell maintenance and tumor progression in the ascites
microenvironment.
A unique down regulation of genes with functional
relevance to protease inhibition, immunosuppressive
tumor microenvironment, and energy and retinoic acid
metabolism, regulator of cell cycle and mediator of anti-
inflammatory reactions was observed in CR tumors.
SerpinA3 (FC > 26) topped the list among the down
regulated proteins. SerpinA3, also known as alpha 1-antic-
hymotrypsin is amember of the serpin super family,which
inhibits the activity of certain proteases, such as cathepsin
G in neutrophils and chymases in mast cells, by cleaving
them into a different conformation [104]. Down regulation
of SerpinA3 expression may protect CR tumor cells from
damage caused by neutrophil- and mast cell- associated
proteolytic activities. Besides SerpinA3, other down reg-
ulated proteins such as HCLS1 [105], SOX18 [106], LY96
[also known as myeloid differentiation factor -2 (MD-2)]
[107], HLA-DRB4 [53], and BCL11A [57] have been
shown to be involved with lymphoangiogenesis, presen-
tation of class II molecules to antigen presenting dendritic
cells, and LPS signalling through Toll-like receptor 4.
Down regulation of these molecules in CR tumor cells
suggests that genes that regulate the activities of cytotoxic
T cells, antigen presenting dendritic cells and differenti-
ation of precursor endothelial cells associated with
infiltrating lymphocytes are dominantly suppressed, sug-
gesting that this mechanisms is used by CR tumors to
escape host immune surveillance. These observations are
consistent with the significant down regulation ofCD99, a
stromal factor expressed on cancer associated fibroblasts
and stromal lymphocytes [108] again supporting reduced
stromal/infiltrating T cell component in CR tumors as
described before [10].
A particularly interesting observation in the CR gene
list was the loss of CRABP2 which previously has been
shown to be over expressed in serous ovarian tumors
[109]. Loss of CRBP2 in CR tumors may indicate con-
comitant loss of vitamin A metabolism and retinoic acid
receptor signalling required for differentiation of ascites
tumor cells. Loss of CRBP2 expression has been shown to
be associated with decreased disease-free survival rates in
Head and Neck Squamous Cell Carcinoma [110].
Interestingly, the two sequential chemotherapy samples
obtained from the same CR patient (CR tumors-As22C
and As22D) displayed close interaction in the PCA plot
suggesting somewhat similar gene expression makeup.
However, on further investigation 16 differentially genes
were identified in these samples. Among these, genes like
APOF [111], KCNH6 [112], KYNU [113], LRAP [114],
MAGT1 [115],MAL [116],MGC26356 andMRP63 were
up regulated by 2.7 to 5.3-folds in As22D compared to
As22C. These up regulated proteins are involved with
lipid transfer, voltage gated potassium channels, biosyn-
thesis of NAD cofactor, magnesium transport and T-cell
mediated immune functions. The down regulated genes
included ADCY3 [117], ASS1 [118], C11orf63, C3ORF34
[119], IL-8 [120], LCN2 [121], LRG1 [122] and MT1A
[123] were down regulated by 2.3 to7.5-folds in As22D
compared to As22C. Among the down regulated proteins
IL-8 has been shown to have tumor promoting effect in
ovarian cancer [120, 124]. It is not clear if the changes in
the above genes is due to administration of a single dose of
cyclophosmide to the patient or is it due to the de novo
changes in the tumor during progression of the disease.
In order to identify ‘dominant’ pathways that may
regulate the chemoresistant and chemonaive phenotype
of ascites-derived tumor cells, we used Ingenuity Pathway
Analysis. Of these, the mitotic pathways regulated by
Polo-like kinase (PLK1), cell cycle: G2/MDamage check-
point regulation and role of checkpoint proteins in cell
cycle checkpoint control topped the list. PLKs are serine/
threonine kinases, which are over expressed in many
cancers and serve as biomarkers and a target for cancer
therapy [125, 126]. PLK1 is expressed only in dividing
cells fromG2 onward and is degraded at the end of mitosis
[125]. PLK1 in combination with CDC25c and CCNB1
regulates mitotic entry, spindle formation and cytokinesis
in human cells [126]. PLK1 also regulates G2-DNA
damage checkpoint and is required for checkpoint recov-
ery following checkpoint inactivation; that is when the
damage is completely repaired and the cells restart the cell
cycle [126]. PLK1 has been shown as an independent
prognostic marker for ovarian cancer patients [127] and
PLK2 as an epigenetic determinant of chemosensitivity
and clinical outcomes in ovarian cancer [128].
In conclusion, we have demonstrated for the first time a
unique and novel pattern of gene expression in isolatedCR
tumors compared to CN tumors obtained from the ascites
of ovarian cancer patients. This preliminary study on a
small sample size has utilised a systematic approach of
studying only the tumor cells isolated from the ascites of
CR and CN patients. We demonstrate an underlying
lineage-specific relationship between high-grade serous
ovarian carcinomas and ascites-derived tumor cells by the
expression of lineage-specific essential gene PAX8.
Unlike most other carcinomas, which dedifferentiate dur-
ing progression and recurrence, recurrent ovarian tumors
in the ascites microenvironment exist as epithelial cells in
the form of spheroids [6, 10]. In that setting, up regulation
of genes associated with cell-cell adhesion, embryonic
stem cells, CSCs and genes antagonistic for migration and
invasion (TGFBR3) defines the true characteristics of CR
tumors in the ascites microenvironment. Concomitant
down regulation of genes involved with host immune
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surveillance provides an immunosuppressive environment
that limits the host immune system to fight the tumor. This
preliminary study, builds the framework of future studies,
which will focus on particular genes and pathways of
interest that may have therapeutic potential in reducing
ascites-associated recurrences in ovarian cancer patients.
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